- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Interventions
- Ramelteon, Placebo
- Drug
- Lead sponsor
- Swedish Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 133
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Basilar Migraine
- Interventions
- Topiramate
- Drug
- Lead sponsor
- Monarch Medical Research
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Episodic Migraine
- Interventions
- Atogepant 60 mg, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 26
- States / cities
- Colton, California • Encino, California • Los Alamitos, California + 20 more
- Conditions
- Migraine
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 45
- States / cities
- Little Rock, Arkansas • Banning, California • Loma Linda, California + 37 more
- Conditions
- Migraine
- Interventions
- levetiracetam, Transcranial Magnetic Stimulation
- Drug · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Migraine
- Interventions
- Atogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- Migraine
- Interventions
- Simvastatin, Vitamin D, Placebo
- Drug · Dietary Supplement · Other
- Lead sponsor
- Rami Burstein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
- Conditions
- Migraine Headache
- Interventions
- Kiko exercises-combines breathing and movement
- Behavioral
- Lead sponsor
- Regional Clinical Research
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Endwell, New York
- Conditions
- Migraine Disorders, Refractory Migraine, Chronic Migraine
- Interventions
- TEMMA Endovascular Treatment
- Device
- Lead sponsor
- Cortex Neurovascular
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Migraine, With or Without Aura
- Interventions
- Atogepant, Placebo-matching Atogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
- Conditions
- Migraine, Major Depressive Disorder
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
- Conditions
- Migraine
- Interventions
- Nerivio
- Device
- Lead sponsor
- Theranica
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Migraine
- Interventions
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 30
- States / cities
- Tempe, Arizona • Colton, California • Los Angeles, California + 27 more
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 962 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Sherman Oaks, California • Stamford, Connecticut + 20 more
- Conditions
- Migraine Headache
- Interventions
- zonisamide
- Drug
- Lead sponsor
- Elan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 13
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 10 more
- Conditions
- Episodic Migraine Headache
- Interventions
- LBR-101 High Dose, LBR-101 Low Dose, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 63
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
- Conditions
- Chronic Migraine
- Interventions
- Atogepant, Placebo for Atogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
- Conditions
- Migraine
- Interventions
- Zavegepant
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Migraine
- Interventions
- ABP-450
- Drug
- Lead sponsor
- AEON Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 44 more
- Conditions
- Migraine Disorders
- Interventions
- Middle Meningeal Artery embolization
- Device
- Lead sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Walnut Creek, California • Hartford, Connecticut • Buffalo, New York + 5 more
- Conditions
- Migraine
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Santa Monica, California • Spring Valley, California • Stamford, Connecticut + 10 more
- Conditions
- Migraine Headache
- Interventions
- Botulinum Toxin Type A
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more